List of Excipients in Branded Drug ACETAMINOPHEN ASPIRIN AND CAFFEINE

Generic Drugs Containing ACETAMINOPHEN ASPIRIN AND CAFFEINE

Subscribe to access the full database, or Start Trial
Company	Ingredient	NDC	Excipient
Better Living Brands LLC	acetaminophen, aspirin and caffeine	21130-074	CELLULOSE, MICROCRYSTALLINE
Better Living Brands LLC	acetaminophen, aspirin and caffeine	21130-074	CROSPOVIDONE
Better Living Brands LLC	acetaminophen, aspirin and caffeine	21130-074	GLYCERYL MONOSTEARATE
Better Living Brands LLC	acetaminophen, aspirin and caffeine	21130-074	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
Better Living Brands LLC	acetaminophen, aspirin and caffeine	21130-074	POLYVINYL ALCOHOL
Better Living Brands LLC	acetaminophen, aspirin and caffeine	21130-074	POVIDONE K30
Better Living Brands LLC	acetaminophen, aspirin and caffeine	21130-074	POVIDONE K90
>Company	>Ingredient	>NDC	>Excipient

What are the Most Frequently-Used Excipients in ACETAMINOPHEN ASPIRIN AND CAFFEINE?

Subscribe to access the full database, or Start Trial
# Of NDCs	Excipient
5	CELLULOSE, MICROCRYSTALLINE
5	CROSPOVIDONE
5	GLYCERYL MONOSTEARATE
5	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
5	POLYVINYL ALCOHOL
5	POVIDONE K30
5	POVIDONE K90
># Of NDCs	>Excipient

Last updated: August 9, 2026

The commercial opportunity for acetaminophen, aspirin, and caffeine products is strongest in differentiated oral solid doses, rapid-release formats, single-dose convenience, and improved tolerability. The active combination is mature and generally available through OTC pathways, so value depends on formulation performance, packaging, branding, regulatory compliance, and channel execution rather than basic composition-of-matter exclusivity.

Acetaminophen, Aspirin, and Caffeine Excipient Strategy and Commercial Opportunities

What is the standard acetaminophen, aspirin, and caffeine formulation?

The best-known formulation is the Excedrin Migraine and Excedrin Extra Strength combination:

Active ingredient	Typical dose per unit
Acetaminophen	250 mg
Aspirin	250 mg
Caffeine	65 mg
Total active load	565 mg

The combination is marketed for temporary relief of headache and migraine symptoms. Acetaminophen provides analgesic and antipyretic activity, aspirin provides analgesic and anti-inflammatory activity, and caffeine is used as an analgesic adjuvant.

The high active load creates the central formulation challenge. A tablet must accommodate more than 560 mg of active ingredients while maintaining acceptable hardness, disintegration, dissolution, swallowability, stability, and manufacturing throughput.

The formulation is typically an immediate-release tablet or caplet. Relevant excipient functions include:

Dilution and tablet weight control
Dry binding and granulation
Lubrication
Flow improvement
Disintegration
Moisture control
Color and appearance
Film coating
Taste and odor masking

The excipient system must account for the different physical properties of the three actives. Acetaminophen can have poor compressibility depending on particle morphology and grade. Aspirin is sensitive to moisture and can hydrolyze to salicylic acid and acetic acid. Caffeine has different particle-size, flow, and crystallinity characteristics from the analgesics.

Which excipients are most important for this drug combination?

The most commercially relevant excipient strategy uses a low-moisture, direct-compression or dry-granulation platform.

Fillers and compression aids

Microcrystalline cellulose is a common choice for improving compactibility and tablet strength. It can support direct compression and reduce dependence on wet granulation, which is useful because aspirin is moisture-sensitive.

Dibasic calcium phosphate can provide density, flow, and low-moisture processing. It is useful where a high active load requires a compact tablet, although its brittle compression behavior must be matched with the particle properties of the actives.

Mannitol can improve mouthfeel and support chewable or orally disintegrating formats. It is less attractive for the lowest-cost conventional tablet because it is generally more expensive than standard cellulose or calcium phosphate systems.

Lactose may be considered for conventional tablets, but compatibility, moisture exposure, particle engineering, and target market requirements must be evaluated. A lactose-free platform can support consumer positioning and reduce formulation complexity for certain markets.

Binders

Povidone and copovidone can improve granule strength and tablet integrity. Their use is more straightforward in dry granulation than in aqueous wet granulation.

Hydroxypropyl cellulose can provide binding and film-forming functionality. Low-substitution grades may also contribute to disintegration.

The binder concentration must remain controlled. Excessive binding can delay disintegration and dissolution, which is counterproductive for a fast-acting headache product.

Disintegrants

Croscarmellose sodium, crospovidone, and sodium starch glycolate are the principal disintegrant candidates.

Crospovidone can support rapid liquid uptake and tablet breakup without significant gelling. Croscarmellose sodium can provide strong swelling-driven disintegration. Sodium starch glycolate is cost-effective but may produce slower or more variable performance if used at excessive concentrations.

A dual-disintegrant system can be commercially attractive when it improves robustness across different tablet compression forces and active-material lots. Any such combination should be justified by dissolution and disintegration data rather than by excipient novelty alone.

Lubricants and glidants

Magnesium stearate is widely used but can reduce wetting and slow dissolution when over-lubrication occurs. This risk is relevant in a high-dose immediate-release product.

Sodium stearyl fumarate can provide an alternative lubrication profile, especially where dissolution sensitivity or over-lubrication is a concern.

Colloidal silicon dioxide can improve flow and reduce hopper-feed variability. The amount must be optimized because excessive glidant can affect blend uniformity, dusting, and tablet appearance.

Coatings

A film coat can improve swallowability, reduce odor, protect the tablet from handling, and support product identification. The coating should have low moisture transmission and should not materially delay immediate release.

A moisture-barrier coating is particularly relevant because aspirin can degrade in humid conditions. Packaging remains more important than coating alone, but the two controls can be designed together.

What excipient risks are specific to aspirin?

Aspirin creates the most important stability constraint in the combination.

Aspirin hydrolysis increases with moisture, heat, and unsuitable packaging conditions. The resulting salicylic acid can produce odor, reduce chemical purity, and affect consumer acceptability. Formulators should control:

Water activity
Residual moisture in excipients
Relative humidity during manufacture
Granulation liquid exposure
Package moisture ingress
Storage temperature
Headspace humidity
Compatibility with alkaline or reactive excipients

A dry process is usually more attractive than conventional aqueous wet granulation. If wet granulation is required, the process must minimize water exposure and demonstrate acceptable aspirin degradation throughout the proposed shelf life.

Excipient selection should be supported by compatibility studies using the final active ratios, not only by binary active-excipient screening. Interactions may differ when acetaminophen, aspirin, and caffeine are present together.

The preferred commercial package is likely a high-barrier blister or bottle with a desiccant, depending on the target channel and cost structure. Unit-dose blister packaging can improve moisture protection, portability, adherence to labeled dosing, and premium positioning. Bottles generally offer lower packaging cost and faster filling but may expose tablets to repeated humidity cycles after opening.

Which formulations offer the strongest commercial opportunities?

Fast-release caplets

The conventional caplet remains the largest and lowest-risk opportunity. Differentiation can come from:

Faster disintegration
More consistent dissolution
Smaller tablet dimensions
Improved film coating
Lower tablet weight
Unit-dose packaging
Private-label or store-brand supply

This segment is price competitive. A formulation patent based only on routine excipient substitution would face substantial validity and enforcement risk unless the claims are tied to unexpected dissolution, stability, manufacturability, or clinical performance.

Gelcaps and liquid-filled capsules

A liquid-filled capsule can improve swallowability and support rapid dispersion, but aspirin stability, capsule-shell compatibility, fill uniformity, leakage, and manufacturing cost become more important.

This format could command a premium if it produces a demonstrated onset or tolerability advantage. It also creates more substantial manufacturing and packaging requirements than a standard tablet.

Effervescent powders and granules

Effervescent products can provide rapid dissolution and a differentiated consumer experience. The principal risks are moisture sensitivity, acid-base compatibility, aspirin stability, packaging cost, and dosing accuracy.

Aspirin-containing effervescent products require careful control of the acid and carbonate system. The platform may be more commercially viable in sachets or stick packs than in multidose bottles.

Powder products

Powder formats can reduce tablet-swallowing barriers and support direct-to-consumer or convenience-channel sales. They may be suitable for headache products sold in sachets or unit-dose pouches.

The formulation must manage taste, aspirin odor, powder segregation, hygroscopicity, and the risk of inaccurate consumer dosing. Flavor systems and high-barrier packaging become central elements of the product.

Chewable and orally disintegrating tablets

These formats can target consumers who have difficulty swallowing conventional caplets. The active load makes a true orally disintegrating product difficult. Taste masking is also challenging because aspirin and acetaminophen can produce an unpleasant sensory profile.

A lower-dose product, multiparticulate system, coated particles, or divided-dose regimen may be more practical than attempting to place the full standard dose into a small orally disintegrating unit.

Modified-release products

Modified release is a weaker opportunity for routine headache treatment because consumers generally expect rapid relief. A sustained-release product could create a distinct use case, but it would require careful clinical and regulatory positioning. It could also complicate the established dosing logic for a combination in which caffeine is intended to enhance acute analgesic activity.

What regulatory pathway applies to this combination?

In the United States, acetaminophen, aspirin, and caffeine products are generally positioned within the OTC analgesic framework. The FDA OTC monograph system and applicable labeling requirements govern active ingredients, doses, indications, warnings, directions, and packaging.

A product that follows the applicable monograph conditions may avoid the need for a product-specific new drug application, subject to current FDA requirements. A formulation that departs materially from monograph conditions may require a different regulatory pathway.

Key regulatory issues include:

Liver warning language for acetaminophen
Gastrointestinal bleeding and ulcer warnings for aspirin
Aspirin use restrictions for certain populations
Caffeine-related labeling and consumer messaging
Maximum daily dose directions
Duplicate acetaminophen warnings across combination products
Child-resistant packaging requirements where applicable
Drug Facts labeling
Stability and expiration dating
Manufacturing under current good manufacturing practices

The FDA’s final OTC monograph framework under the CARES Act changed the administrative process for nonprescription drugs. Sponsors must assess whether the product falls within an applicable monograph order and whether the proposed formulation, labeling, and claims remain compliant.[1]

What patents protect acetaminophen, aspirin, and caffeine products?

The active ingredients are long-established and do not provide meaningful new chemical entity exclusivity for a conventional combination product. Commercial protection is more likely to arise from formulation, manufacturing, packaging, delivery, or brand assets.

Potential patent categories include:

Patent category	Potential claim focus	Commercial strength
Immediate-release formulation	Excipient ratios, compression profile, dissolution	Moderate if performance is unexpected
Moisture-control formulation	Low-water process, barrier coating, stability	Moderate to strong if linked to aspirin stability
Particle engineering	Particle size, morphology, coated particles	Moderate
Rapid-onset delivery	Fast disintegration, dispersion, or absorption	Stronger if supported by clinical data
Taste-masked dosage form	Coated particles, flavor system, multiparticulates	Moderate
Packaging	Moisture-barrier system, unit-dose configuration	Usually narrow
Manufacturing process	Dry granulation, blending, compression sequence	Moderate if difficult to design around
Method of use	Specific headache or migraine regimen	Potentially limited by prior art and OTC labeling
Brand and trade dress	Product name, packaging, consumer recognition	Often more commercially important than patents

A credible freedom-to-operate analysis must review issued and pending claims by jurisdiction, owner, legal status, terminal disclaimers, prosecution history, and litigation record. The Orange Book is relevant only if the product has an FDA-approved NDA or ANDA with listed patents. It is not a complete source for all OTC formulation or packaging patents.

For a standard OTC combination, the principal barrier to generic or private-label entry is usually manufacturing scale, regulatory compliance, brand recognition, retailer access, and quality consistency rather than a strong active-ingredient patent estate.

When does this combination lose exclusivity?

The basic active combination has no practical modern exclusivity period comparable to a new prescription drug. The relevant commercial protections are product-specific.

For branded OTC products, exclusivity can arise from:

Brand recognition
Retail placement
Advertising
Trade dress
Distribution agreements
Product-specific formulation patents
Regulatory exclusivity attached to an approved application, if applicable
Proprietary manufacturing know-how

Generic and private-label products can generally compete when they comply with the applicable FDA requirements and avoid enforceable third-party rights. A formulation patent could delay a specific product design, but it would not necessarily prevent competitors from selling a legally compliant alternative using different excipients, process conditions, packaging, or dosage forms.

What formulation strategy can create defensible IP?

The strongest patent strategy would connect excipient selection to a measurable technical result.

Potential claim concepts include:

A low-moisture tablet containing the three actives and a defined moisture-scavenging or barrier system.
A dry-granulated formulation with specified particle-size ranges and a rapid dissolution profile.
A coated aspirin particle system that limits hydrolysis while maintaining immediate release.
A low-tablet-weight caplet with defined hardness, friability, disintegration, and dissolution characteristics.
A unit-dose package that maintains aspirin impurity levels below a specified threshold through labeled shelf life.
A taste-masked powder or multiparticulate product with defined release and sensory performance.
A process that reduces segregation among the three active ingredients during high-speed compression.

Routine substitution of one standard binder or disintegrant for another is less likely to support durable patent protection. Stronger claims require comparative data showing an unexpected improvement in aspirin stability, dissolution, onset, manufacturability, or consumer use.

Trade secrets may be more effective for blend order, lubrication time, granule density, compression settings, coating parameters, and packaging controls. These process details are difficult to identify from the finished product and can support consistent manufacturing without public disclosure.

What generic entry risks exist for branded products?

The main competitive threats are private-label tablets, national generic brands, powders, and alternate headache combinations.

Competitor type	Entry risk	Main advantage
Store-brand caplets	High	Lower price and retailer distribution
Generic equivalent tablets	High	Familiar dosage and low manufacturing complexity
Aspirin-free products	High	Broader consumer suitability and lower warning burden
Ibuprofen-based products	Moderate to high	Different consumer perception and positioning
Powder sachets	Moderate	Convenience and rapid-use format
Caffeine-free analgesics	Moderate	Broader use among caffeine-sensitive consumers
Premium liquid-filled products	Moderate	Swallowability and perceived speed
Migraine-specific prescription products	Moderate	Targeted clinical positioning

Aspirin creates a commercial limitation because some consumers cannot use aspirin due to gastrointestinal risk, bleeding concerns, anticoagulant use, allergy, age-related restrictions, or pregnancy-related warnings. Products without aspirin can address a broader market, although they do not reproduce the same active combination.

How does this combination compare with competing headache products?

Product type	Key actives	Main commercial positioning	Formulation implication
Triple analgesic combination	Acetaminophen, aspirin, caffeine	Headache and migraine relief	High active load and aspirin stability
Acetaminophen plus caffeine	Acetaminophen, caffeine	Aspirin-free headache relief	Easier safety positioning and broader audience
Ibuprofen tablet	Ibuprofen	Anti-inflammatory pain relief	Lower active load but different GI and renal warnings
Aspirin tablet	Aspirin	Pain and inflammation	Simpler formulation, aspirin-specific risk
Prescription migraine product	Varies	Targeted migraine treatment	Higher regulatory and clinical differentiation

The triple combination has a recognizable consumer proposition, but its warning profile and active load create constraints. The most attractive adjacent opportunity may be an aspirin-free acetaminophen and caffeine formulation, while the strongest premium opportunity within the triple combination is likely a faster, more stable, easier-to-swallow product.

What licensing and commercial opportunities exist?

Licensing opportunities are more likely to involve technology platforms than ownership of the three active ingredients.

Potential partners include:

OTC manufacturers seeking private-label supply
Contract development and manufacturing organizations
Film-coating and moisture-barrier specialists
Multiparticulate and taste-masking technology providers
Blister and high-barrier packaging suppliers
Retail pharmacy chains
E-commerce health brands
International OTC licensees

The most valuable transaction assets would include a validated formulation, scalable manufacturing process, stability data, regulatory-ready labeling, and freedom-to-operate analysis. A patent application without comparative technical data would have lower licensing value.

Commercial models include:

Out-licensing a differentiated formulation
Supplying finished dosage units to retailers
Licensing a powder or sachet platform
Developing regional brands under a manufacturing agreement
Offering a branded-generic product with premium packaging
Acquiring a small OTC brand with established distribution

What is the recommended excipient and product-development strategy?

A practical development sequence is:

Start with direct compression and dry granulation to limit moisture exposure.
Screen microcrystalline cellulose, dibasic calcium phosphate, and selected co-processed excipients.
Compare crospovidone, croscarmellose sodium, and sodium starch glycolate for rapid disintegration.
Minimize magnesium stearate exposure and evaluate sodium stearyl fumarate where dissolution is sensitive.
Test low-moisture film coatings and high-barrier packaging together.
Establish aspirin impurity, acetaminophen degradation, caffeine assay, dissolution, and content-uniformity targets.
Develop a unit-dose blister variant for premium channels.
Build formulation claims around demonstrated stability or release advantages.
Retain process parameters and blend controls as trade secrets where patent disclosure would provide little additional protection.
Confirm FDA monograph and labeling compliance before selecting final commercial claims.

Key Takeaways

The standard commercial dose is 250 mg acetaminophen, 250 mg aspirin, and 65 mg caffeine per unit.
Aspirin moisture sensitivity is the primary excipient and packaging constraint.
Dry granulation or direct compression is generally more attractive than aqueous wet granulation.
Microcrystalline cellulose, dibasic calcium phosphate, crospovidone, croscarmellose sodium, colloidal silicon dioxide, and controlled lubrication are logical development candidates.
The strongest commercial formats are fast-release caplets, unit-dose blisters, powders, and premium swallowability-focused products.
The active ingredients are mature, so formulation, process, packaging, branding, and distribution provide the main opportunities.
Patent value depends on unexpected performance, such as improved aspirin stability, faster dissolution, lower tablet weight, or better manufacturability.
Generic and private-label entry risk is high for conventional tablets.
An aspirin-free acetaminophen and caffeine product offers broader consumer access but is a separate competitive proposition.
Trade secrets may protect manufacturing know-how more effectively than narrow excipient-substitution patents.

FAQs

Can acetaminophen, aspirin, and caffeine be formulated as a single effervescent product?

Yes. The format is technically feasible, but moisture control, aspirin stability, acid-base compatibility, taste, packaging, and dose uniformity are critical development issues. Single-dose foil sachets are generally more suitable than multidose containers.

Which excipient best protects aspirin from degradation?

No single excipient provides complete protection. A low-moisture formulation, limited water exposure, compatible excipient system, moisture-barrier coating, and high-barrier package must be evaluated as an integrated control strategy.

Is a fast-dissolving tablet patentable for this combination?

Potentially, but rapid disintegration alone may be insufficient. Stronger patent protection requires defined formulation or process parameters linked to unexpected dissolution, stability, onset, or manufacturing results.

Does the Orange Book list all patents covering these OTC products?

No. The Orange Book primarily covers patents associated with listed FDA-approved drug applications. It does not provide a complete record of all OTC formulation, packaging, manufacturing, trademark, or trade-secret rights.

What is the most attractive commercial format for a new entrant?

A unit-dose, moisture-protected fast-release product has the clearest differentiation path. It can combine convenience, stability, portability, and premium packaging while avoiding reliance on active-ingredient exclusivity.

References

U.S. Food and Drug Administration. (2024). Over-the-counter monograph drugs. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs/otc-monograph-drugs
U.S. Food and Drug Administration. (2024). Drug facts labeling. https://www.fda.gov/drugs/drug-information-consumers/drug-facts-labeling
U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.
U.S. Food and Drug Administration. (2023). Acetaminophen information. https://www.fda.gov/drugs/information-drug-class/acetaminophen-information
U.S. Food and Drug Administration. (2023). Aspirin: Questions and answers. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aspirin-questions-and-answers

More… ↓

⤷ Start Trial